Vimarsana
Biggest News Aggregation in the World

Page 48 - Immunic Inc News Today : Breaking News, Live Updates & Top Stories | Vimarsana

Stay updated with breaking news from Immunic Inc. Get real-time updates on events, politics, business, and more. Visit us for reliable news and exclusive interviews.

Top News In Immunic Inc Today - Breaking & Trending Today

DGAP-News: Immunic, Inc. to Participate in Scientific, Investor and Industry Conferences in April - Vimarsana News

DGAP-News: Immunic, Inc. to Participate in Scientific, Investor and Industry Conferences in April

DGAP-News: Immunic, Inc. to Participate in Scientific, Investor and Industry Conferences in April Immunic, Inc. to Participate in Scientific, Investor and Industry Conferences in April 13.04.2021 / 12:30 Immunic, Inc. to Participate in Scientific, Investor and Industry Conferences in April NEW YORK, April 13, 2021 - Immunic, Inc. (Nasdaq: IMUX), a clinical-stage biopharmaceutical company developing a pipeline of selective oral immunology therapies aimed at treating chronic inflammatory and autoimmune diseases, today announced participation in the following scientific, investor and industry ...

Immunic, Inc. to Participate in Scientific, Investor and Industry Conferences in April - Vimarsana News

Immunic, Inc. to Participate in Scientific, Investor and Industry Conferences in April

/PRNewswire/ -- Immunic, Inc. (Nasdaq: IMUX), a clinical-stage biopharmaceutical company developing a pipeline of selective oral immunology therapies aimed at...

DGAP-News: Immunic, Inc. to Participate in Industry and Investor Conferences in March - Vimarsana News

DGAP-News: Immunic, Inc. to Participate in Industry and Investor Conferences in March

DGAP-News: Immunic, Inc. to Participate in Industry and Investor Conferences in March Immunic, Inc. to Participate in Industry and Investor Conferences in March 02.03.2021 / 12:30 Immunic, Inc. to Participate in Industry and Investor Conferences in March NEW YORK, March 2, 2021 - Immunic, Inc. (Nasdaq: IMUX), a clinical-stage biopharmaceutical company developing a pipeline of selective oral immunology therapies aimed at treating chronic inflammatory and autoimmune diseases, today announced management's participation in the following industry and investor conferences in March: - March 8-9: ...

Immunic, Inc. Announces Positive Top-Line Data From Investigator-Sponsored Phase 2 Proof-of-Concept Clinical Trial of IMU-838 in Primary Sclerosing Cholangitis - Vimarsana News

Immunic, Inc. Announces Positive Top-Line Data From Investigator-Sponsored Phase 2 Proof-of-Concept Clinical Trial of IMU-838 in Primary Sclerosing Cholangitis

 Immunic, Inc. (Nasdaq: IMUX),  a clinical-stage biopharmaceutical company developing a pipeline of selective oral immunology therapies aimed at treating chronic inflammatory and autoimmune diseases, today announced positive top-line data from an investigator-sponsored phase 2 proof-of-concept clinical trial of IMU-838 in primary sclerosing cholangitis (PSC). This single-arm, open-label, exploratory study was designed to investigate IMU-838's potential to improve various biochemical parameters in PSC patients and help determine whether any such activity warrants further investigation in ran...

Investegate |Immunic, Inc. Announcements | Immunic, Inc.: Immunic, Inc. Announces Positive Top-Line Data From Investigator-Sponsored Phase 2 Proof-of-Concept Clinical Trial of IMU-838 in Primary Sclerosing Cholangitis - Vimarsana News

Investegate |Immunic, Inc. Announcements | Immunic, Inc.: Immunic, Inc. Announces Positive Top-Line Data From Investigator-Sponsored Phase 2 Proof-of-Concept Clinical Trial of IMU-838 in Primary Sclerosing Cholangitis

Investegate announcements from Immunic, Inc., Immunic, Inc. Announces Positive Top-Line Data From Investigator-Sponsored Phase 2 Proof-of-Concept Clinical Trial of IMU-838 in Primary Sclerosing Cholangitis